MORAb-109 / Eisai - LARVOL DELTA

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models. (PubMed, Clin Transl Med) - No abstract available

Journal • Preclinical • Gynecologic Cancers • Oncology • FOLR1 • MSLN

Preclinical evaluation of farletuzumab ecteribulin (FZEC) and MORAb-109, antibody-drug conjugates (ADCs) targeting folate receptor alpha and mesothelin, in high-risk gynaecological cancers. (LCC 2025) - " Eribulin demonstrated activity in 11 out of 15 gynaecological cancer models, outperforming the standard anti-microtubule agent, paclitaxel, despite 80% of models being resistant to cisplatin. The 15 aggressive gynaecological cancer PDX models showed remarkable responses to FZEC and MORAb-109 when FRA and/or MSLN expression was positive and ABCB1 expression was low. Given the limited treatment options for advanced gynaecological cancer, our findings underscore the urgent need to include these cancers in eribulin ADC trials early in the disease course."

Preclinical • Carcinosarcoma • Clear Cell Carcinoma • Endometrial Serous Adenocarcinoma • Gynecologic Cancers • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Uterine Cancer • ABCB1 • FOLR1 • MSLN

Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers. (ASCO 2023) - "The anti-microtubule agent (AMA) paclitaxel is used in first-line treatment of most gynecologic cancers; however, the AMA eribulin is known to have additional anticancer properties (Goto et al...Despite most (80%) models being cisplatin refractory, 11/15 responded to eribulin with the 4 non-responders having high MDR1 expression and being from previously treated patients... Responses to FZEC and MORAb-109 correlated with FRA and MSLN expression, with equivalent or better activity compared to eribulin in target-positive PDX models of HGSOC, USC and OCCA. >* Models tested for FRA and MSLN expression (not all were tested for ADC activity). ** FZEC response in FRA+ PDXs."

Preclinical • Endometrial Serous Adenocarcinoma • Gynecologic Cancers • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Sarcoma • Uterine Cancer • ABCB1 • FOLR1 • MSLN

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 (PRNewswire) - "Additional data from Eisai's pipeline include a poster presentation of findings from a Phase 1b study of E7386, a CREB-binding protein (CBP) / β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced HCC...and the small cell lung cancer cohort of a Phase 1b/2 trial evaluating E7389-LF, a new liposomal formulation of eribulin, in combination with nivolumab...Insights from preclinical testing of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, and MORAb-109, antibody drug conjugates (ADC), in rare gynecologic cancers will also be published online."

P1 data • P1/2 data • Preclinical • Gastrointestinal Cancer • Gynecologic Cancers • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor